Abstract Metabolomics is a valuable tool for biomarker screening of colorectal cancer (CRC). In this study, we profiled the urinary metabolomes of patients enrolled in a prospective patient cohort (ColoCare). We aimed to determine changes in the metabolome of the longer clinical follow-up and ascertain candidate markers with possibly prognostic significance. In total, 199 urine samples from CRC patients prior to surgery (n = 97) or 1-8 days postsurgery (n = 12), and then after 6 (n = 52) and 12 months (n = 38) were analyzed using both GC-MS and 1 H-NMR. Both datasets were analyzed separately with built in uni-and multivariate analyses of Metaboanalyst 2.0. Furthermore, adjusted linear mixed effects regression models were constructed. Many concentrations of the metabolites derived from the gut microbiome were affected by CRC surgery, presumably indicating a tumor-induced shift in bacterial species. Associations of the microbial metabolites with disease stage indicate an important role of the gut microbiome in CRC. We were able to differentiate the metabolite profiles of pre-surgery CRC patients from those at any post-surgery timepoint using a multivariate model containing 20 marker metabolites (AUCROC = 0.89; 95 % CI 0.84-0.95). This is one of the first metabolomic studies to follow CRC patients in a prospective setting with repeated urine sampling over time. We were able to confirm markers initially identified in case-control studies and metabolites which may represent prognostic biomarker candidates of CRC.
Introduction
In 2012, colorectal cancer (CRC) was the second most common cancer in Europe, and the second most common cause of death from cancer with almost 215,000 deaths each year (Ferlay et al. 2013 ). In the US, CRC was the third most common cancer for both genders with more than 50,000 deaths in 2013 (ACS 2013) . While improvements in the early detection of disease occurrence are crucial, biomarkers for tertiary prevention, to improve the prediction of disease recurrence, are urgently needed as well. To date, treatment and clinical follow-up of CRC patients largely follows standardized guidelines. Only a few markers for personalized therapies exist, such as KRAS mutation as a predictive biomarker for anti-EGFR therapy in metastasized patients (Normanno et al. 2013) . Moreover, the detection of early stage metastasis is limited by the sensitivity of currently available tumor markers, CA19-9 and CEA, and imaging technologies such as abdominal sonography, computed tomography (CT) and magnetic resonance imaging (MRI) (Bellomi et al. 2005) .
''Omics-technologies'' such as transcriptomics, proteomics and metabolomics may be particularly well suited to explore the underlying biology of complex, multifactorial diseases such as CRC (Nambiar et al. 2010) . However, none of the omics-technique has yet been fully successful in the accurate diagnosis of CRC or the prediction of patients' prognosis (Nambiar et al. 2010) .
Metabolomic studies on CRC to date focus either on profiling of tumor tissue Denkert et al. 2008; Mal et al. 2009 Mal et al. , 2012 to gain insight into cancer biology, or use serum (Farshidfar et al. 2012; Kondo et al. 2011; Leichtle et al. 2012; Nishiumi et al. 2012; Qiu et al. 2009; Ritchie et al. 2010 ) and/or urine samples (Cheng et al. 2012; Ma et al. 2009; Qiu et al. 2010; Wang et al. 2010 ) with the aim to detect novel markers for early disease detection. As previously reviewed by our own group (Liesenfeld et al. 2013) , most studies have used a simple case-control study design with only a few investigations conducting follow-up studies with repeated sampling of biospecimens over time (Farshidfar et al. 2012; Ritchie et al. 2010) .
In this GC-MS-and 1 H-NMR-based metabolomics study, we profiled 199 urine samples at different study timepoints in a prospective CRC patient cohort, the ColoCare study. We aimed to compare urinary metabolomes of CRC patients prior to surgery with those a few days and at 6 and 12 months postsurgery, assessing potential effects related to the primary therapeutic intervention. Additionally, we aimed to detect changes in the metabolome in the longer follow-up and describe initial predictors as candidate markers with possible prognostic significance. To the best of our knowledge, this study is one of the first CRC metabolomic approaches embedded in a prospective study design which describes associations with clinicopathologic factors and trends over time.
Materials and methods

Study population
This study is part of the international prospective cohort study, ColoCare, recruiting newly-diagnosed CRC patients prior to surgery with the goal to investigate predictors of cancer recurrence, survival, treatment toxicities and health-related quality of life. Within the study, extensive follow-up observations over the duration of 5 years are being performed: three follow-up timepoints in year one, followed by one each year thereafter, including a comprehensive collection of biospecimens and data. The ColoCare study has been approved by the ethics committee of the medical faculty at the University of Heidelberg and study participants provided their written informed consent. Patients were categorized according to the American Joint Committee on Cancer (AJCC) staging system based on histopathologic findings. Both patients with colon carcinoma (ICD-18) and patients with rectal or rectosigmoidal cancer were included. Urine, generally overnight fasting, was collected from patients at baseline, prior to surgery (n = 97), and in some cases from patients 1-8 days postsurgery (n = 12). As part of the ColoCare follow-up regime, additional biosepecimens were obtained approximately 6 and 12 months post-enrollment at the National Center of Tumor Diseases, Heidelberg (NCT). Spot urine samples from these respective follow-up visits were included (see Table 1 for study population and sample availability and Supplementary  Table S6 for patient overlap between timepoints). If patients underwent adjuvant chemotherapy, follow-up visits were scheduled at least 2 weeks after their last chemotherapy cycle had been completed. Urine samples were aliquoted immediately and stored at -80°C until analysis. Self-reported food and fluid intake before sample collection was monitored during follow-up visits. Patients who reported alcohol or tobacco use 24 h prior to urine collection were excluded from this dataset.
Chemicals and Reagents
HPLC-grade methanol and acetonitrile were purchased from VWR International (Fontenay-sous-Bois, France). Sodium 3-(trimethylsilyl)-propionate-2,2,3,3-d4 99 % D (TSP) was purchased from Euriso-top (Saint-Aubin Cedex, France). Bis(trimethylsilyl)trifluoroacetamide (BSTFA) containing 1 % trimethylchlorosilane was purchased from Supelco (Bellefonte, USA). Deuterium oxide (D 2 O), pyridine, methoxyamineÁHCl, L-4-chlorophenylalanine, uridine 5 0 -diphosphoglucuronic acid trisodium salt (UGA), saturated alkane mixture (C 7 -C 40 ) and all analytical reference standards were purchased from Sigma Aldrich (Steinheim, Germany) at the highest purity available.
Sample preparation
For GC-MS analysis, the method for urine sample preparation was adapted from the literature (Cheng et al. 2012 ); see also Supplementary Data, but without urease treatment because low enzyme specificity resulting in distorted metabolite levels have been reported using this approach by several research groups (Kind et al. 2007; Perroud et al. Prospective colorectal cancer urinary metabolomics pilot study 999 2006). Pooled quality control (QC) samples and Kovat's alkane mixtures were injected with each analytical batch. For 1 H-NMR, 540 lL urine were spiked with 60 lL K 2 HPO 4 /NaH 2 PO 4 buffer in D 2 O (pH 6.5, 1.5 M) (Xiao et al. 2009 ) containing 10 mM TSP to a final D 2 O concentration of 10 % (v/v) for lock and shim purposes and TSP concentration of 1 mM. QC samples were run at the beginning and end of each analytical batch.
GC-MS data acquisition
Analysis was carried out on an Agilent 6890 GC/5973 MS single quadrupole system. Aliquots of 1 lL were injected onto a HP-5 MS fused silica column (30 m 9 0.25 mm; 0.25 lm film thickness of the 5 % phenyl 95 % dimethylpolysiloxane stationary phase; Agilent J&W Scientific) in splitless mode. Chromatographic and mass spectrometric conditions are described in the Supplementary Data.
2.5
1 H-NMR data acquisition 1 H-NMR spectra were acquired using a Bruker Avance II NMR spectrometer equipped with a 5-mm, inverse-configuration probe with triple-axis gradient capability at a field strength of 14.1 T operating at 600.1 MHz for 1 H. Spectra were acquired at 25°C using the 1D NOESY with pre-saturation pulse program resident in the spectrometer software. Detailed 1 H-NMR acquisition parameters can be found in the Supplementary Data.
2.6 Data pre-processing GC-MS raw files were converted to netCDF format and processed with MZMine 2.0 (Pluskal et al. 2010 ) (see Supplementary Data for parameters). Chromatographic peaks were annotated based on four different levels following literature recommendations (Sumner et al. 2007 ). Level 1: authentic reference standard available, level 2: electron impact (EI) spectral match ([75 %) and Kovat's retention indices (RI) match (±20) to the NIST 2011 database, level 3: (EI) spectral match ([75 %) to multiple components of a chemical class (i.e. sugars), level 4: unknown metabolite. A data matrix was constructed using the peak area of the base peak of each metabolite divided by the peak area of the internal standard (L-4-chlorophenylalanine). Artefact peaks resulting from the derivatization process and interferences due to urea were removed from the dataset. Urea interferences have been noted before in urinary GC-MS studies, leading to effects such as ion suppression, peak distortion and/or column overload (Kind et al. 2007) . We excluded metabolites with [30 % coefficient of variance (CV) in QC samples from the final data analysis (Dunn et al. 2011) . For amino-group containing metabolites that showed multiple peaks due to serial derivatization (Kanani et al. 2008) , we used the sum of the peak areas of all the detected derivatives for analysis.
For 1 H-NMR, a targeted profiling approach using spectral fitting was applied. Bruker NMR files were imported into Chenomx NMR suite software (Chenomx, Edmonton, Canada), spline baseline and automatic shim correction were performed prior to manual fitting of spectra against the built-in library version 7.7.
Data analysis
Data analysis was conducted using the Metaboanalyst 2.0 toolbox program (Xia et al. 2012 ) separately for GC-MS and 1 H-NMR data. Most metabolites in our dataset deviated from a normal distribution. Furthermore, peak areas spanned several orders of magnitude. We therefore normalized our datasets to account for differences in fluid intake, as well as to render metabolites equally important and more normally distributed (van den Berg et al. 2006) .
1 H-NMR data were normalized to creatinine (lmol/mmol creatinine), log transformed and auto-scaled in Metaboanalyst. Since the choice of normalization might influence the results, it has been recommended therefore to use two different normalization techniques (Warrack et al. 2009 ). Because creatinine was in a non-linear dynamic range of the detector for concentrated samples for GC-MS analysis (see Supplementary Table S1 ), GC-MS data was normalized by sum, log-transformed and auto-scaled in Metaboanalyst prior to analysis. If [40 % missing values were present for a given metabolite, the metabolite was not used for data analysis.
For model building, we tested and compared three different methods for missing value imputation (minimum, mean and median). Non-parametric univariate analyses (WilcoxonMann-Whitney tests) were used for the comparison of two groups and one-way ANOVA for multiple group comparison. Furthermore, multivariate partial least squares discriminant analysis (PLS-DA) models were constructed with Metaboanalyst. Finally, to account for possible confounding variables, linear mixed effects regression models, were built into the statistical software R 3.0.1 (www.r-project. org) adjusting raw p-values for sex, disease stage, BMI, adjuvant and neoadjuvant chemo-and radiotherapy, NSAID use, smoking and fasting status. The linear mixed effects models were built with the ''lmer'' function of the package lme4 (Bates et al. 2013 ) using patient ID as random-effect term, while the p-values for the fixed-effects terms were calculated using an approximate F-test based on the Kenward-Roger approach as implemented in the package pbkrtest (Højsgaard 2013) . As a final step, adjusted p-values (p adjust) were corrected for multiple testing (FDR) (Benjamini and Hochberg 1995) .
Binary class discrimination abilities (i.e. comparing prevs. post-surgery patients) were assessed with ROCCET toolbox to construct receiver operator characteristic curves (ROC) (Xia et al. 2013 ).
Pathway visualization
To visualize the overall effect of therapeutic intervention on CRC patients' metabolomes, we used the approach of chemical similarity (PubChem ID) and biochemical pathway mapping (KEGG ID) with the MetaMapp tool and Cytoscape as previously described (Barupal et al. 2012 ).
Results
From the GC-MS data, a total of 198 metabolites were annotated after removal of all artifacts arising from derivatization. More than 85 % (169 metabolites) passed the initial QC criteria of\30 % CV in the QC samples. The median % CV in QC samples across all 198 metabolites was 12.3 indicating a robust analytical method. A total of 161 metabolites were annotated by 1 H-NMR spectral fitting. The reproducibility was generally higher than for GC-MS (median % CV 7.3; see also Supplementary Fig. 4 ). Without chromatographic separation prior to 1 H-NMR analysis, the fitting of signals in crowded regions of the spectra (e.g. 3-5 ppm) is problematic due to spectral overlap. We therefore validated both methodologies against each other by applying a conservative approach: metabolites with a Spearman rank correlation coefficient \0.5 over the whole dataset (GC-MS peak area vs. 1 H-NMR concentrations) were subject to manual inspection and deleted from either the 1 H-NMR or GC-MS dataset (see Supplementary Table S1 for the exclusion criteria). The remaining cleaned datasets, containing 168 metabolites for GC-MS and 152 metabolites for 1 H-NMR, produced very consistent results throughout the analyses (vide infra).
Patient urine metabolomes change after surgery
A primary aim of this study was to monitor patient urine metabolomes on a prospective basis. We therefore compared two groups:
(a) pre-surgery patients, still bearing a tumor, and (b) patients at 1-8 days post-surgery (n = 12), at 6 months follow-up (n = 52), and at 12 months follow-up (n = 38). Corresponding fold-change plots for GC-MS and 1 H-NMR are shown in Fig. 1 and are further summarized in Supplementary Table S2 . We additionally carried out a sub-analysis only for those patients with matching observations between pre-surgery and follow up timepoints (Results summarized in Supplementary Table S7 ). In total, 39 metabolites detected by GC-MS remained significant after adjustment for covariables and multiple testing (FDR \ 0.05), whereas only 2-aminobutyrate was found to be significant in our 1 H-NMR analysis. Many unknown metabolites (level 3 or 4 identification) were of high significance in the GC-MS dataset, however, they were absent from the 1 H-NMR data due to its use as a targeted profiling technique in our study.
Metabolites from microbial origin
Many significant metabolites, were presumably of microbial origin, for example 2,3-butanediol, maleamate, hydroquinone, guajacol, pyrogallol and 2-, 3-and 4-hydroxyhippurate. All of them were diminished in pre-surgery CRC patients' urine compared to post-surgery urine (fold change \1, Fig. 1a ). In contrast, two microbial metabolites, p-cresol and its glucuronide (p-cresol-b-Oglucuronide), were found to be excreted in higher concentrations in pre-surgery patients (p adjusted \0.05 \FDR).
Metabolites from amino acid metabolism
Several amino acids (see Fig. 1 ) were detected at significantly lower concentration in the urine of pre-surgery patients compared to post-surgical timepoints by both GC-MS and 1 H-NMR analysis, but only asparagine, tyrosine and phenylalanine reached significance after FDR correction. Some valine-metabolites (3-hydroxyisobutyrate and c-glutamyl-valine) were present in higher concentrations pre-surgery. Additionally, concentrations of some tryptophan catabolites, e.g. 3-indoxylsulfate (FDR = 0.06) and indole-3-acetate, were found to be altered.
Oncometabolites
We also observed significantly decreased excretions of myo-inositol, a precursor of the phosphoinositol-3-kinase (PI3K) pathway. The oncometabolite 2-hydroxyglutarate was elevated in pre-surgery patients' urine.
Effects of chemo-and radiotherapy
We observed a modulating effect of adjuvant chemo-and radiotherapy on the described changes in metabolite levels when pre-and post-surgery individuals were compared (see Supplementary Table S3 ). The differences between preand post-surgical samples were more pronounced among patients undergoing adjuvant chemotherapy. Nevertheless, the same direction of change in metabolite levels was observed in patients who only underwent surgery with no adjuvant treatment. In contrast, neoadjuvant treatment, prior to surgery, was not associated with patients' metabolomes.
Pathway visualization of therapeutic effects
Overall effects of the therapeutic intervention were visualized with MetaMapp and cytoscape, where groups of altered metabolites were clustered together according to their chemical similarity (see Fig. 2 ).
Distinguishing early and late stage disease
To investigate whether metabolites in the urine could discriminate CRC patients by disease stage, pre-surgery patients were compared based on tumor staging and grouped as follows: A PLS-DA score plot of pre-surgery CRC patients by stage is illustrated in Supplementary Fig. S3 . Additionally, discriminating metabolites were selected using one-way ANOVA. Sixteen metabolites in both GC-MS and 1 H-NMR datasets were found to significantly discriminate CRC stages (p-values \ 0.05, Table 2 ), but only two of them remained significant after adjusting for multiple testing, namely a dipeptide of hydroxyproline (Hyp-Hyp) and p-cresol-b-O-glucuronide. The latter compound was determined to be a level 2 metabolite but showed a high correlation with p-cresol (data not shown). We therefore chose to synthesize the glucuronide enzymatically (Supplementary Material) to unequivocally identify this phase II metabolite of p-cresol as the b-O-glucuronide.
We observed that Hyp-Hyp was increased in intermediate-and late-stage pre-surgery patients when compared to early-stage patients. We also found hippurate to be c Fig. 2 Mapped pathway for the therapeutic effects on the urinary metabolomes of colorectal cancer patients. Metabolites were mapped according to their biochemical pathway (KEGG-bold line) and chemical similarity (PubChem ID-light gray line). Fold changes and adjusted/FDR-corrected p values were abstracted by comparing patients pre-and post-surgery. Only metabolites with an adjusted/ FDR-corrected p value \ 0.1 were labeled as increased/decreased excreted in higher concentrations in intermediate-and latestage patients compared to early-stage patients and detected similar trends by both GC-MS and 1 H-NMR analysis. Urea levels were diminished in late-stage patients compared to early-or intermediate-stage patients. Glycerol, galactarate and butyrate levels were increased only in late stage CRCs, whereas the opposite trend was observed for carnitine. Moreover, we detected 3 unknowns, 2 glucuronides and one sugar alcohol that enabled discrimination between the different stages in our GC-MS dataset.
Generally, early-stage patients were easier to distinguish from more advanced stages of the disease, whereas intermediate stages were only poorly differentiated from either of these groups (see Supplementary Fig. S3 ).
Colon versus rectal cancer patients
Among pre-surgery CRC patients enrolled in our study, 54 had rectal/43 colon cancer. Ten metabolites were significantly different after adjusting for all covariates and multiple testing when pre-surgery colon and rectal cancer patients were compared (Table 3) . 3-(3-Hydroxyphenyl)-3-hydroxypropionate and 3-indoxylsulfate were excreted in higher concentrations in colon cancer patients, whereas the opposite was true for cis-aconitic acid, glutamate ? pyroglutamate (GC-MS), dopamine, arabitol and two unidentified metabolites. We noted that some of the previously mentioned gut microbiota-associated metabolites were excreted in higher concentrations from colon cancer patients, although the differences were not statistically significant after multiple testing. Interestingly, Hyp-Hyp, detected at higher concentrations in late-stage patients was also elevated in colon carcinoma patients compared to rectal-cancer patients (p adjusted = 0.084). We furthermore compared pre-surgery patients who received neoadjuvant therapy (n = 36) against pre-surgery patients without any therapy prior to surgery (n = 50). No metabolites differed significantly after adjusting for multiple testing.
Metabolite markers for CRC
We chose to build two binary classification models for the differentiation of tumor bearing individuals (pre-surgery CRC patients) from patients after therapeutic intervention: We manually selected those metabolites that were significant after adjusting for covariates (p adjusted), with fewer than 10 % missing values, where a direct effect of surgery was seen in patients 1-8 days post-surgery (labeled as ''post'') and maintained over a period of up to 1 year (6 month and 12 month follow-up). Metabolites fulfilling these requirements are summarized in Supplementary Table S4 . We selected 4 amino acids (tyrosine, threonine, tryptophan and glycine), 10 metabolites with high confidence in identification (level 1 or 2) and 6 unidentified, but highly significant species. These 20 metabolites were used to construct a multivariate model (based on partial least squares-discriminant analysis) with the ROCCET toolbox (Xia et al. 2013 ).
Model 2: automatic metabolite selection
A second model was constructed by selecting the ten best differentiating metabolites from both GC-MS and 1 H-NMR data, based on their univariate ROC. Metabolite selection was performed with fasted individuals only (n = 108) to avoid marker selection due to differences in fasting state. This second model, based on these 20 automatically selected metabolites, was constructed using the same ROCCET parameters as in Model 1.
Both metabolite sets were used to discriminate pre-from post-surgery individuals in the full dataset and a subset of fasted individuals. The results are illustrated in Fig. 3 with metabolites and univariate AUCs provided in the Supplementary Data.
We were able to differentiate pre-from post-surgery patients with high accuracy in both models. The method for imputation of missing values only had a marginal effect on the overall model performance (see Supplementary Data). The automatically selected set of metabolites performed slightly better than the manually selected set (cf. Figure 3a vs. b). Overall, only small differences in the model performance were observed between a full dataset and a dataset consisting of fasted patients (AUCs in the range of 0.85-0.92), indicating that both metabolite sets were independent of a patients' fasting state. Furthermore, excluding the small group of 1-8 days post-surgery patients from the analyses did not significantly change the results.
Discussion
Our results show that urine metabolomes of CRC patients prior to surgery can be distinguished from those of patients after surgery. This indicates that patients' metabolomes are primarily affected by the disease or removal of the tumor and substantial parts of the intestine, although an exacerbating effect of adjuvant chemotherapy was also observed. Furthermore, we were able to identify several metabolites associated with particular disease stages as potential candidates for prognostic markers. Generally, we observed many metabolites with unknown identity (level 3 or 4) to be highly and significantly different.
Differences by stage: degradation products
of collagen as candidates for prognostic biomarkers for CRC
We were able to identify several urinary metabolites that distinguished early-from late-stage CRC patients. We identified Hyp-Hyp at higher levels in late-stage cancer patients' urine. The metabolite was also significantly altered in the urine of hepatocellular cancer patients (Wu et al. 2009 ). Hydroxyproline itself, a major component of collagen, showed no difference in excretion levels by stage. It has long been known that cancer cells need to degrade extracellular matrix components in order to disseminate through connective tissue (Deryugina and Quigley 2006). Dipeptides of hydroxyproline may be derived from the process of disseminating tumor cells, degrading collagen during the process of early metastasis, although the definitive origin of the metabolite remains to be determined. Interestingly, CRC patients prior to surgical intervention and post-surgery patients did not show a significantly different urinary excretion of Hyp-Hyp. However, colon cancer patients excreted higher levels of Hyp-Hyp compared to rectal cancer patients-an observation that was not explained by neoadjuvant therapy. Future mechanistic studies are needed to determine whether or not dipeptides of Hyp are formed during early Fig. 3 Receiver operator characteristic (ROC) curves for the differentiation between pre-and post-surgery CRC patients. a Model 1 using manual variable selection; ROC curve and score plot from a partial least squares-discriminant analysis (PLS-DA) model containing 20 metabolites for all patients in our dataset (bold line) and a subset of fasted patients (dashed line). b Model 2 using automatic variable selection; ROC curve and score plot from a partial least squares-discriminant analysis (PLS-DA) model containing 20 metabolites for all patients in our dataset (bold line) and a subset of fasted patients (dashed line) metastasis, and if the marker has a prognostic value for CRC patients.
4.2 Post-surgery urine metabolome changes indicative of the importance of the gut microbiome
We found many small aromatic compounds (see Fig. 2 top right) lowered in CRC patients prior to surgery compared to post-surgery timepoints. In contrast, p-cresol and its glucuronide tended to be present at higher concentrations in presurgical patients. Moreover, p-cresol and its glucuronide were of value for discerning the different stages of the disease (Table 3) . Some of these gut-microbial-derived metabolites have been previously found to discriminate healthy controls from CRC patients. Qui et al. and Cheng et al. both reported altered p-cresol levels in the urine of CRC patients compared to healthy controls, but with an opposite direction (Cheng et al. 2012; Qiu et al. 2010) . We not only observed elevated concentrations of p-cresol and its glucuronide in the late stages of CRC, but, moreover, surgical intervention markedly reduced the levels by approximately 50 %. Interestingly, Zhang et al. found the glucuronide of pcresol to be up-regulated in rats with chemically induced colitis (Zhang et al. 2012) . p-Cresol and its glucuronide may therefore reflect a gut-microbiota induced inflammatory response (Zhang et al. 2012) . Studies led by Bone et al. showed that p-cresol species arise primarily from tyrosine conversion by anaerobic bacteria in the left colon (Bone et al. 1976) . The tumor promoting activities of p-cresol and related compounds have been known for decades (Boutwell and Bosch 1959) . Taken together, our findings suggest that surgical removal of the tumor and parts of the intestine may affect microbial metabolites and possibly the microbiota itself, with adjuvant chemotherapy exacerbating this effect. Gut microbial activity can affect the tumor environment through the production of toxins (Heavey and Rowland 2004) , mutagens (Carman et al. 1988) or reactive oxygen intermediates, as previous demonstrated (Owen et al. 2000) . On the other hand, the tumor microenvironment can also influence and select bacterial communities, for example by providing a niche for certain species (Marchesi et al. 2011) . Therapeutic intervention and/or removal of parts of the intestine are likely to change the bacterial population, which in turn leads to an altered metabolism in the gut.
Our results support the hypothesis that the gut microbiota play a more important role for colon cancer than for rectal or rectosigmoidal cancer patients. Several of the microbiome-associated metabolites were found to be different between colon and rectum carcinoma patients, irrespective of prior neoadjuvant treatment (see Table 3 ), which is in line with the findings that these compounds are formed directly in the colon (Bone et al. 1976 ).
Many of these bacterial metabolites are absorbed by the intestine and further metabolized by the host and/or excreted in the urine. The identified glucuronide of p-cresol is an example of these detoxification mechanisms. However, future studies will have to establish how the composition of the microbiome (assessed, for example, by genotyping analyses) and/or a decrease in absorption area due to surgical intervention is associated with the metabolites excreted in urine. To clearly differentiate between effects of surgery and disease, additional studies are needed, i.e. the inclusion of patients who undergo new surgical techniques such as minimal invasive CRC surgery (Biondi et al. 2013 ).
Long-known hallmarks of cancer monitored
by the metabolomic profile of urine in CRC patients
Amino acid metabolism
Although the concentrations of some amino acids were primarily affected by co-variables such as fasting status, many other amino acids were excreted at lower concentrations in the urine of pre-surgery CRC patients. Alterations in the amino acid profiles of cancer patients have been described multiple times (Leichtle et al. 2012; Maeda et al. 2010; Miyagi et al. 2011 ). Miyagi et al. compared targeted plasma amino acid profiles of various cancer entities against controls and also reported decreased levels for most amino acids in CRC, except for isoleucine, proline and glycine (Miyagi et al. 2011) . Decreased levels of 2-oxobutyrate in combination with an increase in 2-aminobutyrate might favor an increased amino acid catabolism of threonine (Paxton et al. 1986; Steele 1982) . On the other hand, lower urinary excretion might also reflect an increased uptake of amino acids by the tumor for protein biosynthesis, accompanied by cellular turnover and tumor growth. Consistently, we observed lower urinary urea levels among late-stage patients. Urinary urea, as the prime end-product of amino acid catabolism, is an indicator of nitrogen excretion. Lower levels of urinary urea in latestage cancers might indicate less nitrogen flux into catabolic reactions, and a likely higher amino acid flux into protein biosynthesis. This is in line with the theory that tumors act as ''nitrogen sinks'' on a systemic level (Kern and Norton 1988) . The theory is further supported by animal studies observing an initial increase in urinary urea excretion after transplantation of colon adenocarinomas in mice, but a decrease below the baseline level at late stages of tumor growth (Beck and Tisdale 1989) .
Tryptophan catabolism
Several members of tryptophan metabolism were affected by the surgical intervention: tryptophan itself (0.82-fold) as well as xanthurenate (0.79-fold) and indole-3-acetate (0.80-fold) were diminished in pre-surgery compared to post-surgery patients, whereas 3-indoxylsulfate levels were increased 1.46-fold (Fig. 1) . Cheng et al. also reported diminished levels of tryptophan catabolites in CRC patients compared to healthy individuals (Cheng et al. 2012) . Tryptophan is the precursor of several neurotransmitters and hormones such as serotonin and melatonin, but also of kynurenine, an endogenous ligand of the arylhydrocarbon receptor, promoting a tumor progressive mechanism (Opitz et al. 2011) . Tryptophan catabolites may therefore play a distinct role in tumor metabolism as well as modulation of the immune system (Moffett and Namboodiri 2003) .
Oncometabolites
We observed moderately higher (1.27-fold) urinary excretion of the oncometabolite 2-hydroxyglutarate in patients at pre-compared to post-surgery. Oncometabolic activities of 2-hydroxyglutarate have recently been discovered (Losman and Kaelin 2013) : 2-hydroxyglutarate can promote epigenetically driven carcinogenesis by directly inhibiting histone lysine demethylases (Chowdhury et al. 2011 ) and 5-methylcytosine hydroxylases (Pollard et al. 2005) . The metabolite itself has been described as being derived from the neomorphic activity of mutated isocitrate dehydrogenase (IDH).
myo-Inositol was diminished by 0.43-(GC-MS) and 0.68-fold ( 1 H-NMR), respectively, in pre-surgery CRC patients compared to post-surgery. myo-Inositol and its derivatives have previously been associated with different cancer types/ biological matrices in varying directions of change (Aa et al. 2012; Perroud et al. 2006; Thysell et al. 2010) . Denkert et al. reported lower levels of an inositol stereoisomer in colon cancer tissue compared to normal colon mucosa (Denkert et al. 2008) , in concordance with the observed lower urinary myo-inositol levels in pre-surgery, tumor-bearing patients in our study. Another group compared CRC patients at different stages and observed that inositol was less abundant in tissues of CRC liver metastasis (Farshidfar et al. 2012) . Inositol might therefore play a role in cellular signaling, via its link to the phosphoinositol-3-kinase PI3K pathway, and thus impacting CRC pathogenesis.
Strength and limitations of this study
A strength of this study was the large sample size including a prospective setting with repeated measurements in a significant proportion of patients. Furthermore, two complementary analytical techniques (GC-MS and NMR) were used. A main limitation of our study was the low sensitivity of NMR and single-quadrupole MS as well as the low unit mass accuracy for the latter technique. Subsequently, we were unable to identify a number of metabolites of high significance, by not being able to conduct more sophisticated library searches or sum formula calculations. For follow-up studies it would be desirable to use more sophisticated instrumentation, such as high accuracy tandem mass spectrometry in combination with either LC or chemical ionization GC to acquire mass spectrometric information on the molecular ions and fragmentation patterns of potential unknown cancer biomarkers.
Concluding remarks
To the best of our knowledge, this study is one of the first reporting urine metabolomic data with repeated sampling from a prospective CRC patient cohort. While most studies published thus far have compared CRC patients to healthy controls, we were able to monitor patient metabolomes over time. Moreover, we used two complementary methods, GC-MS and 1 H-NMR, enabling us to independently validate our findings.
Surgical intervention had a significant impact on several metabolites derived from the gut microbiota. Moreover, amino acids and downstream metabolites of aromatic amino acids were altered. We were able to formulate a discrimination model consisting of twenty marker metabolites to differentiate pre-from post-surgery CRC patients with good accuracy. Additionally, we observed a dipeptide of hydroxyproline, together with p-cresol and its glucuronide, to be present in higher concentrations in the urine of late stage CRC patients. To further evaluate whether these candidate metabolites are of prognostic value for the clinical outcome of patients, a validation study with continued follow-up over a longer time period will be needed.
